Construction of new retroviral producer cells from adenoviral and retroviral vectors

Gene Therapy

Volumn 5, Issue 9, 1998, Pages 1251-1258

  Lin, X ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Adenoviral vectors; Gene delivery; Packaging cells; Retroviral vectors

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ARTICLE; GENE TARGETING; GENETIC MARKER; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; PRIORITY JOURNAL; RETROVIRUS; TARGET CELL;

EID: 0031694564     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300720     Document Type: Article

References (44)

1. Blaese RM et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 470-474.
2. Blaese RM, Anderson WF. The ADA human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 327-329.
3. Bordignon C et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA immunodeficient patients. Science 1995; 270: 470-474.
4. Grossman M et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-341.
5. Chuah MKL, Vandendriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995; 6: 1363-1377.
6. Colledge WH, Evans MJ. Cystic fibrosis gene therapy. Br Med Bull 1995; 51: 82-90.
7. Blaese RM et al. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther 1995; 2: 291-297.
8. Smith LC, Eisensmith RC, Woo SL. Gene therapy in heart disease Adv Exp Med Biol 1995; 369: 77-88.
9. Riley DJ, Lee WH. The potential of gene therapy for treatment of kidney diseases. Semin Nephrol 1995; 15: 57-69.
10. Yu M, Poeschla E, Wong-Staal F. Progress towards gene therapy for HTV infection. Gene Therapy 1994; 1: 13-26.
11. Afione SA, Conrad CK, Flotte TR. Gene therapy vectors as drug delivery systems. Clin Pharmacokinet 1995; 28: 181-189.
12. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62: 191-217.
13. Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol 1995; 49: 807-838.
14. Vile RG, Russell SJ. Retroviruses as vectors. Br Med Bull 1995; 51: 12-30.
15. Rettinger SD et al. Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc Natl Acad Sci USA 1994; 91: 1460-1464.
16. Salmons B, Saller RM, Baumann JG, Gunzburg WH. Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia 1995; 1: S53-S60.
17. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
18. Rother RP et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody. J Exp Med 1995; 182: 1345-1355.
19. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA. Human serum lyses RNA tumor viruses. Nature 1975; 257: 612-614.
20. Lin X, Tang J. A new retrovirus-based in vivo gene delivery strategy. In: POSTERS section, CHI (Cambridge Healthtech Institute) meeting abstracts, Technological Advances for Gene Therapy November 29-30, 1994, Washington, DC.
21. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
22. Wei CM, Gibson M, Spear PG, Scolnick EM. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J Virol 1981; 39: 935-944.
23. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus. J Virol 1993; 67: 5911-5921.
24. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8801-8806.
25. Felsenstein KM, Goff SP. Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J Virol 1988; 62: 2179-2182.
26. Miller AD, Verma IM. Two base changes restore infectivity to a noninfectious molecular clone of Moloney murine leukemia virus (pMoMLV-1). J Virol 1984; 49: 214-222.
27. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224: 497-500.
28. Noguiez-Hellin P, Meur MR, Salzmann JL, Klatzmann D. Plasmoviruses: nonviral/viral vectors for gene therapy. Proc Natl Acad Sci USA 1996; 93: 4175-4180.
29. Savard N, Cosset FL, Epstein AL. Defective herpes simplex virus type 1 vectors harboring gag, pol and env genes can be used to rescue defective retrovirus vectors. J Virol 1997; 71: 4111-4117.
30. Bilbao G et al. Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 1997; 11: 624-634.
31. Feng M et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector Nat Biotechnol 1997; 15: 866-870.
32. Yoshida Y, Emi N, Hamada H. VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem Biophys Res Commun 1997; 232: 379-382.
33. Yoshida Y, Hamada H. Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem Biophys Res Commun 1997; 230: 426-430.
34. Bramson JL, Graham FL, Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol 1995; 6: 590-595
35. Wilson JM. Adenoviruses as gene-delivery vehicles. Molec Med 1996; 334: 1185-1187.
36. Zabner J et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996; 97: 1504-1511.
37. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
38. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988; 62: 1120-1124.
39. Markowitz D et al. Retroviral gene transfer using safe and efficient packaging cell lines. Ann NY Acad Sci 1990; 612: 407-414.
40. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Meth Enzymol 1993; 217: 581-599.
41. Adam MA, Ramesh N, Miller AD, Osborne WRA. Internal initiation of translation in retroviral vectors carrying picorna-virus 5 nontranslated regions. J Virol 1991; 65: 4985-4990.
42. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ (ed). Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols. Humana Press: Clifton, NJ, 1991, pp 109-128.
43. Hitt M, Bett AJ, Prevec L, Graham FL. Construction and propagation of human adenovirus vectors. In: Cell Biology: A Laboratory Handbook. Academic Press: New York, 1994, pp 479-490.
44. Gartner S, Popovic M. Virus isolation and production. In: Aldovini A, Walker BD (eds). Techniques in HIV Research. Stockton Press: New York, 1990, pp 53-70.